Geode Capital Management
NVLN

Geode Capital Management’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Geode Capital Management’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-84,353
Closed -$61K – 4303
2019
Q3 		$61K Sell
84,353
-1,056
-1% -$765 ﹤0.01% 4042
2019
Q2 		$66K Buy
85,409
+528
+0.6% +$587 ﹤0.01% 4042
2019
Q1 		$104K Buy
84,881
+1,980
+2% +$2.25K ﹤0.01% 3888
2018
Q4 		$71K Buy
82,901
+26,003
+46% +$29.4K ﹤0.01% 3926
2018
Q3 		$168K Buy
56,898
+1,473
+3% +$5.21K ﹤0.01% 3802
2018
Q2 		$203K Sell
55,425
-29,086
-34% -$117K ﹤0.01% 3716
2018
Q1 		$295K Buy
84,511
+6,157
+8% +$26.1K ﹤0.01% 3574
2017
Q4 		$244K Buy
78,354
+40,194
+105% +$193K ﹤0.01% 3618
2017
Q3 		$268K Buy
38,160
+12,438
+48% +$99.7K ﹤0.01% 3571
2017
Q2 		$237K Buy
+25,722
New +$248K ﹤0.01% 3619

Other funds holding NVLN

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Geode Capital Management's NVLN Position: Q4 2019 in Review

Geode Capital Management sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 84,353 shares — an estimated $61K sold.

Geode Capital Management first reported a position in NVLN in Q2 2017 and held it in 10 quarters. The position peaked at $295K in Q1 2018. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

  • Geode Capital Management reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
  • Geode Capital Management sold 84,353 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $61K.
  • Geode Capital Management first reported a position in Novelion Therapeutics Inc. Common Shares in Q2 2017 and held it in 10 quarters.
  • Geode Capital Management's Novelion Therapeutics Inc. Common Shares position peaked at $295K in Q1 2018.
  • 7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on Geode Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.